Controversial

I wouldn’t put Ducera above Moelis/Evercore, but the folks at Ducera have crushed it from inception and it’s absolutely a firm on the rise and considered an EB. Would put Ducera RX above Greenhill RX. Ducera’s still small but they punch above their weight in the RX space for sure, and the firm has begun getting the recognition it deserves in terms of exit opps at the junior level. I do agree with the comment above that culture leaves something to be desired for, but I think that’s more in terms of WLB. They absolutely grind juniors to the bone there, but I haven’t heard any horror stories about seniors being dicks/unreasonable to juniors. Definitely a place to work really, REALLY hard, and I would say it’s worth it if you can bear the work.

 

Not sure why I’m getting MS for this comment. I have a good friend who went through Ducera’s analyst program and I’m basing my comment on his experience. If anyone has any legitimate counterpoints, list them. Otherwise I’ll just assume it’s salty GHL interns throwing crap

 

Evercore RX guy here, and I have friends at both Ducera and Greenhill RX. Personally, I'd argue that Greenhill RX is still a better junior experience overall. From the perspective of a junior, you should be taking the biggest name possible without sacrificing too much experience and personal wellbeing. Greenhill RX will open up far more doors, especially if you have any interest in buy-side (Greenhill punches above its weight class for exits because they have an institutional 2-and-out culture and supporting analysts in leaving). Greenhill RX is pretty sweaty as well, but Ducera is materially sweatier, and at the end of the day Greenhill RX is no slouch in terms of deal flow so you'll still get a good analyst experience.

 
Most Helpful

Greenhill's core senior team led by Augustine is definitely legit in the space. Also, for their size, they've been doing decently in terms of deal flow (checked reorg league tables and they're roughly where Ducera is, and off the top of my head I know they were involved in NAC and also do a lot of advisory work for Carlyle and Apollo with portco RX/distressed M&A/recaps). You also have to keep in mind that Greenhill RX is roughly the same size if not smaller than Ducera, so deal flow per head is still comparable.

Also, from the junior perspective, optionality/brand name is just as important if not more important than deal experience, and Greenhill beats out Ducera by quite a margin there.

 

Laughing at all these pissy Greenhill analysts throwing MS at the thought of Ducera being a better bank, even though it’s true (and will become more and more evident in the next couple years as GHL continues to fall down the league tables)

 

Ducera was #17 in the league tables in 2022 and greenhill was even worse, not even in top 10 IMO

 

An associate from there DM'd me on LinkedIn during my summer analyst stint to poach me for FT. Hopped on an "introductory call" and she immediately started grilling me about niche Rx technicals and asking why my gpa is so low (I had a 3.5 at the time). Just bad vibes, red flags everywhere. Going to a BB now instead

 

Ducera is the below all of those listed and is definitely not an EB. Most juniors there are from non-targets and non-traditional IB backgrounds, which isn't end-all-be-all but says something.

Not in the same universe as PWP/EVR/MOCO. Ducera does basically all creditor mandates, while those guys won't touch creditor stuff unless its for a big deal.

I'd still choose Greenhill over them any day given how bad the Ducera culture is. Despite Greenhill's decline, it still has name recognition and is a well-known investment bank (whereas nobody except credit people know Ducera). Additionally, GHL RX is still solid, Neil Augustine leads it who is very respected in the space.

Those rankings comparing fees / deal wins aren't super helpful since so many RX deals aren't public and won't be included. 

 

I’m no ducera shill, but to your point on non traditional backgrounds. Ducera purposely markets themselves towards that since Michael Cramer himself didn’t come from the greatest background. It’s the idea of finding the guy with the largest chip on the shoulder and cranking him.

they generally have really tough interviews, relative to the SA level, which require you to know your stuff. If you can make it through 8 or ten interviews, they’ll take you regardless of your background. 

 

By saying those guys don’t go after creditor mandates unless it’s a big deal shows you know nothing about rx. One peak into the Reorg advisor database and you’ll see those names listed on a ton of creditor mandates on smaller cap stacks.

 

What is the pay roughly for first year at Ducera ? More than the top EB?

 

Per a friend - first years this year got 110k base, 90-110 bonus range. Definitely not "more than top EB" 

 

Occaecati quia magni alias. Nisi consequatur voluptatem aliquam aliquid sed corporis. Aut et consectetur dolores qui aut.

Et voluptatum sed eum atque amet rem cum qui. Ea ipsam dolorem explicabo ut autem. Vel eaque eveniet rem dolores sint inventore dolor similique. Sequi hic ipsa sed facere quia corrupti.

Voluptates fuga voluptates vel natus. Reiciendis enim voluptas nemo voluptas ut aut. Modi non tempore dolorem et rerum veniam. Ab non asperiores eum illum.

Et blanditiis accusamus sit fuga maxime eveniet voluptas ea. Vel et ab quo molestiae commodi. Numquam accusamus reprehenderit ut voluptatum amet nobis quas. Nemo repellendus ut odit nisi aspernatur dicta.

Career Advancement Opportunities

May 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 04 97.1%

Overall Employee Satisfaction

May 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

May 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

May 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (20) $385
  • Associates (88) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (67) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Betsy Massar's picture
Betsy Massar
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
CompBanker's picture
CompBanker
98.9
6
dosk17's picture
dosk17
98.9
7
GameTheory's picture
GameTheory
98.9
8
kanon's picture
kanon
98.9
9
Kenny_Powers_CFA's picture
Kenny_Powers_CFA
98.8
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”